Anbio Biotechnology (NNNN) fair value analysis
Nasdaq · Updated 2026-10-19
NNNN price how computed
Valuation status
No fair-value estimate yetNNNN has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for NNNN yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $3.13
- Sector
- Healthcare
- 12-month range
- $3.13–$41.11
- Market cap
- $137M
- From 52-week high
- -92.4%
- Shares outstanding
- 43.9M
- Rank in Healthcare by quality score
- #255 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
I don't have reliable information about a company with the ticker symbol NNNN on Nasdaq. To provide accurate factual prose about Anbio Biotechnology as requested, I would need verified information about the company's operations and geographic presence, which I cannot confidently provide without risking inaccuracy. If you can provide specific details about this company or verify the ticker symbol, I'd be happy to write the two sentences following your guidelines.
NNNN currently ranks #255 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $137M
- Gross margin
- 81.5%
- Shares outstanding
- 43.9M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 24 · oversold
- 50-day average
- $6.58
- 200-day average
- $18.87
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Last 3 quarters vs consensus
- 2 beat, 1 missed
- Quarter by quarter
- 2025-09 ▲ beat
2025-03 ▼ miss
2024-09 ▲ beat
What our data shows for NNNN
- Shares are trading in the lower third of their 12-month price range of $3.13–$41.11.
- The 14-day relative strength index sits at an oversold 24.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- NNNN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the NNNN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for NNNN show that the RSI zone shifted from neutral to oversold this week. The current valuation verdict remains awaiting full valuation. These changes reflect recent price movement in the Healthcare sector stock.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is NNNN stock undervalued?
TickrTrends has no fair-value estimate for NNNN yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is NNNN's TickrTrends verdict?
NNNN is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does NNNN compare to other Healthcare stocks?
NNNN ranks #255 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is NNNN overbought or oversold?
NNNN's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does NNNN usually beat earnings estimates?
Over its last 3 reported quarters NNNN beat the consensus estimate 2 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.